A

Axsome Therapeutics
D

AXSM

90.840
USD
1.16
(1.29%)
Market Closed
Volume
15,771
EPS
-5
Div Yield
-
P/E
-14
Market Cap
4,402,322,236
Related Instruments
    A
    ACAD
    0.140
    (0.84%)
    16.880 USD
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    BIIB
    BIIB
    -0.780
    (-0.53%)
    146.590 USD
    B
    BMRN
    0.695
    (1.07%)
    65.680 USD
    I
    INCY
    1.910
    (2.85%)
    68.910 USD
    L
    LGND
    1.050
    (0.92%)
    114.800 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    S
    SRPT
    -0.470
    (-0.39%)
    118.970 USD
    VRTX
    VRTX
    0.58
    (0.15%)
    397.15 USD
    More
News

Title: Axsome Therapeutics

Sector: Healthcare
Industry: Biotechnology
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.